Key Takeaways ALMS surged 95.3% after envudeucitinib met all endpoints in two phase III plaque psoriasis studies.Envudeucitinib delivered strong PASI and sPGA skin clearance results in moderate-to-severe plaque psoriasis.ALMS plans to submit an NDA to the FDA for envudeucitinib in plaque psoriasis in 2H 2026.Shares of Alumis (ALMS) surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III studies — ONWARD1 and ONWARD2 — which evaluated its pipeline candidate, envudeuc ...